Cargando…
The Changing Landscape of Type 2 Diabetes: The Role of Incretin-Based Therapies in Managed Care Outcomes
BACKGROUND: The prevalence of diabetes is growing in the United States and, for many patients, blood glucose continues to be poorly managed. Significantly, more than half of people with type 2 diabetes mellitus (T2DM) have hemoglobin A1Cs greater than 7%. Several factors contribute to the failure to...
Autores principales: | Triplitt, Curtis, McGill, Janet B., Porte Jr., Daniel, Conner, Christopher S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438357/ https://www.ncbi.nlm.nih.gov/pubmed/18062735 http://dx.doi.org/10.18553/jmcp.2007.13.9-c.1 |
Ejemplares similares
-
What Are Incretins, and How Will They Influence the Management of Type 2 Diabetes?
por: Bonde, Lawrence, et al.
Publicado: (2006) -
Incretin Mimetics: Promising New Therapeutic Options in the Treatment of Type 2 Diabetes
por: Gleeson, Jeremy M., et al.
Publicado: (2005) -
Evidence‐based treatment of hyperglycaemia with incretin therapies in patients with type 2 diabetes and advanced chronic kidney disease
por: Tuttle, Katherine R., et al.
Publicado: (2020) -
Introduction
por: McGill, Janet
Publicado: (2018) -
The Changing Landscape of Hypertension and the Evolving Role of Vasodilatory Beta-Blockers
por: Bakris, George L., et al.
Publicado: (2007)